Digital Health Reshaping MedTech Industry as Consumers Demand “Anywhere, Everywhere” Healthcare, Accenture and AdvaMed Report Finds
NEW YORK; Nov. 9, 2022 – The medical technology (MedTech) industry is being reshaped by digital health and consumers' expectations to receive care how, when and where they want, according to a new report from Accenture (NYSE: ACN) and AdvaMed.
November 09, 2022
Emerging Technologies Ushering the Life Sciences Industry into the Metaverse, according to Accenture Report
NEW YORK; Aug. 22, 2022 – Accenture’s (NYSE: ACN) Life Sciences Technology Vision 2022 report explores the technology trends that will transform how biopharmaceutical and medical technology companies solve manufacturing and device problems, improve equity in clinical trial participation and build more resilient supply chains to provide patients and healthcare professionals with more personalized experiences.
August 22, 2022
Most Companies Struggling to be Relevant to Their Customers, Accenture Report Finds
NEW YORK; July 26, 2022 – The vast majority (88%) of executives1 believe that customers and employees are changing faster than they can change their businesses, which is leading to a crisis of relevance, according to a new report from Accenture (NYSE: ACN).
July 26, 2022
Accenture Accelerates Data-Driven Decision Making for Lupin
NEW DELHI, India; June 20, 2022 – Lupin Limited (Lupin), a global pharmaceutical company has collaborated with Accenture (NYSE: ACN) to enable its data driven transformation journey for improved business agility, performance, and operational efficiency.
June 20, 2022
Accenture Named a Leader in Healthcare Payer Digital Services PEAK Matrix® Assessment by Everest Group
NEW YORK; June 2, 2022 – Accenture (NYSE: ACN) has been named a Leader in the healthcare payer digital services provider landscape in a recent report from Everest Group.
June 02, 2022
IDC MarketScape Positions Accenture a Leader in Life Science Sales and Marketing IT Outsourcing Services
NEW YORK; April 28, 2022 – Accenture (NYSE: ACN) is positioned as a leader in the IDC MarketScape analysis of life science sales and marketing IT outsourcing services in 2022.
April 28, 2022
Accenture Joins AI4BetterHearts Data Collaborative
NEW YORK; March 29, 2022 – Accenture (NYSE: ACN) has joined AI4BetterHearts, a global data collaborative founded by Microsoft and the Novartis Foundation, that aims to help stakeholders —
from policy makers to patients — make better decisions about heart health and improve the health of entire populations.
from policy makers to patients — make better decisions about heart health and improve the health of entire populations.
March 29, 2022
Nine Out of Ten Healthcare Executives Say That Health Equity Initiatives are a Top Business Priority, According to Accenture and HIMSS Insights
NEW YORK; March 15, 2022 – New research from Accenture (NYSE: ACN) and HIMSS Market Insights reveals that 93% of U.S. healthcare executives believe that health equity initiatives are important and 89% agree that such initiatives are part of their core business strategy. However, only slightly more than a third (36%) have a specific budget dedicated to advancing their health equity agendas.
March 15, 2022
Accenture and Microsoft to Assist Mt. Sinai Health System on Five-Year Transformation Journey to Cloud
NEW YORK; March 1, 2022 – Accenture (NYSE: ACN) and Microsoft (NYSE: MSFT) will assist the Mount Sinai Health System (Mount Sinai) with its transition to the cloud to help enable innovation at a much faster pace. By modernizing its infrastructure, Mount Sinai will be able to reinvest cost-savings and focus on its healthcare mission.
March 01, 2022
Accenture Helping Astellas Pharma Create Next-Generation Cloud-Based IT Core Platform for Advanced Real-Time Decision Making
TOKYO; Feb. 24, 2022 – Accenture (NYSE: ACN) helped Astellas Pharma Inc. create a cloud-based core IT platform that serves as the foundation for an advanced, data-driven management model for the company’s global operations. The new platform has been rolled out in Japan, the Americas and EMEA, with plans for further deployments.
February 24, 2022